VTX:NOVN - Novartis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
CHF 78.38 +0.34 (+0.44 %)
(As of 06/20/2018 01:25 AM ET)
Previous CloseCHF 78.36
Today's RangeCHF 77.72 - CHF 78.50
52-Week RangeCHF 72.45 - CHF 88.30
Volume11.21 million shs
Average Volume5.98 million shs
Market Capitalization$206.54 billion
P/E RatioN/A
Dividend Yield3.57%
BetaN/A
Novartis logoNovan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolVTX:NOVN
CUSIPN/A
Phone+41-61-3241111

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins15.47%
Return on Equity11.16%
Return on Assets6.10%

Miscellaneous

EmployeesN/A
Outstanding Shares2,330,000,000

Novartis (VTX:NOVN) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the VTX under the ticker symbol "NOVN."

What price target have analysts set for NOVN?

19 brokerages have issued twelve-month target prices for Novartis' shares. Their forecasts range from CHF 70 to CHF 98. On average, they expect Novartis' stock price to reach CHF 87.21 in the next twelve months. View Analyst Ratings for Novartis.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Mr. Robert Alexander Ingram, Exec. Chairman (Age 76)
  • Mr. G. Kelly Martin, CEO & Director (Age 59)
  • Dr. Nathan Stasko Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
  • Mr. Jeff N. Hunter, CFO, Chief Bus. Officer, Exec. VP & Company Sec. (Age 61)
  • Mr. Andrew Novak, VP & Chief Accounting Officer

Has Novartis been receiving favorable news coverage?

News articles about NOVN stock have trended somewhat positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novartis earned a media sentiment score of 0.05 on Accern's scale. They also gave headlines about the company an impact score of 47.68 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

What is Novartis' stock price today?

One share of NOVN stock can currently be purchased for approximately CHF 78.38.

How big of a company is Novartis?

Novartis has a market capitalization of $206.54 billion.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.


MarketBeat Community Rating for Novartis (NOVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.